The United States Supreme Court has Amgen vs. Sanofi This could have significant implications both for the question of inventability that has plagued life sciences patents, but also for the broader definition of the modern role of the patent system in the future innovation economy. One case. Specifically, the question of what a genus claim entails in terms of validation becomes an issue. Should the enablement standard be governed by written § 112 statutory requirements and the specification only teach a person skilled in the art how to “make and use” the claimed invention? , would rely on adding to the lower court-based standard that the specification must allow one of ordinary skill in the art to “come to the full scope of the claimed embodiments” without undue experimentation? ?
While there is little doubt that this answer will play an important role in the future of life sciences, especially pharmaceutical patents, the court’s view is that the patent system’s subtleties encourage innovation by allowing companies to take advantage of it. It can only help shape a healthy balance. It prevents their work and others from copying it, while also preventing land grabbing that can have a stifling effect on innovation.
Case
amgen vs sanofi With a long history of litigation dating back nearly a decade, the parties involved swap turns of offense and defense, and two jurors fall to Amgen’s side, but district court and Federal Circuit judges are the final judges. decided in favor of Sanofi. At the heart of the battle are competing versions of cholesterol-lowering drugs made by both companies. Amgen manufactures Repatha, Sanofi manufactures Praluent, and he is responsible for US sales by Regeneron. This drug is a monoclonal antibody that lowers levels of LDL (or low-density lipoprotein) cholesterol (also known as “bad cholesterol”). Amgen initially sued, claiming that the patent protecting Repatha was infringed by her Praluent. Regeneron and Sanofi argued that Amgen’s patent was not valid in the first place.
- Sanofi Amgen claims monopoly over an entire genus of functionally defined claims that have not been validated because they cover thousands of possible antibodies, but the application only provides a limited number of examples. Sanofi’s claim rests on the full range of validation criteria of the Federal Circuit.
- Amgen argues that the Federal Circuit is insane on enablement law – it defies more than a century of Supreme Court precedent on the issue, violates the role of jurors, and violates patents. imposes a full range of requirements not contained in the law. Frustrate the purpose. Amgen’s key claim is that their application provides the roadmap necessary for those skilled in the art to make and use the drug and all species of interest without undue experimentation.
Genus Claim: A Historic Path to Pharmaceutical ROI
Validation, like its evil brother, eligibility, is a two-fold reason for refusal and invalidation, historically less common, but in immunology, molecular biology, chemistry and diagnostics. are becoming more and more common in unpredictable areas such as This is due to what are called genus claims, an important patent feature for the chemical, biotech and pharmaceutical industries. Derived from traditional biological definitions, genera are groups defined by common characteristics, and species are logical divisions of genera. In chemistry, biotechnology, and pharmaceutical patents, genus claims cover groups of structurally and/or functionally related chemical entities, whereas species claims cover single chemical compounds, which are members of the same family. It does not cover analogues, derivatives or compounds.
The reason this is especially important in pharmaceuticals is that one successful drug must be able to recoup huge R&D dollars from the countless failures that preceded it. This requires sufficient coverage and exclusivity over a period of time. It is fairly easy to design many drugs if the patent only narrowly claims a particular chemical class. They have new, non-invasive treatments based on R&D investments they haven’t made. Historically, the broader genus claim has been the overarching tool of choice for many innovators in the field because it is impractical to do so.
The death of Genes Creme?
Where the genus claim has run into problems is the interpretation of one of the core laws governing patentability and the expansion of the forum base. This fundamental tenet of patent law is the concept of validation. When a patent is published, the information it contains becomes part of the public record, ensuring that society receives something useful in exchange for the exclusive rights granted to the inventor. It is intended to This is a great bargain for the patent system. Codified in Section 112 of the United States Code, Title 35 is the minimum requirement regarding the quality and quantity of information that must be included in a patent application to justify the grant of a patent. Section 112 basically states that a patent application must have a complete, distinct states that the invention must be described in concise and precise terms. Those skilled in the art to make and use the invention (enablement requirement). The Supreme Court decision of 1916 set the standard for determining whether a specification satisfies the enablement requirement by raising the question of whether the experimentation necessary to practice the invention was unreasonable or unreasonable. We have further defined the criteria. To date, the law does not use the term “undue experimentation,” but the claimed invention must be enabled so that a person skilled in the art can make and use the invention without undue experimentation. has been interpreted as
If the Supreme Court relies on the Federal Circuit’s application of the evolving enablement standard, genus-level coverage must arrive at the full scope of the claimed embodiments without undue experimentation. Possible species, or at least most species, which the genus claim is intended to cover.
Episode summary
With only the slightest bit of prejudice, I can’t think of anyone who could help solve all of this — a host who has spent an academic and professional career at the intersection of life sciences and patent law. Dr. Ashley Sloat has a background in microbiology and immunology and is currently President and Director of Patent Strategy for Aurora. She leads today’s discussion, along with our All-Star Patent Panel, exploring:
- of scientific background Regarding the antibodies necessary to understand the claim.
- simple Medical history Amgen vs Sanofi.
- Overview of Enabler The tests that have historically been applied in the courts and how they apply to this case.
- unresolved issues and potential unintended consequences The Supreme Court decision addresses only possibilities and ignores written explanations.
- look deeply into Highly Unpredictable Physiological Effects – What are reasonable criteria for teaching a person skilled in the art to make and use inventions that are inherently long, labor intensive, and complex processes?
This was a very persuasive argument with very persuasive arguments and made for a very nice and lively conversation with the panel members, going through the complexities and fundamental issues that the courts had to face. I am emphasizing
High Court High Stakes
Regardless of how this plays out, it’s hard to imagine the High Court’s ruling not having a material impact on the industry. It shows that it is coming. The District Court and Federal Circuit ruled one way, with the Attorney General recommending not to litigate the Supreme Court, and the Court’s scant coverage of litigation on petitions, and litigation on patent law. Considering we barely covered it, there’s little reason why. To believe that the Supreme Court will take up this case merely to rubber stamp its earlier judgment.
Either way, the stakes are incredibly high and there is a very important balance to be had in achieving all of this. Life-changing drug patents need broader protection to have real value. But the enablement requirement is a check for a system that prevents large-scale land grabs and exclusive rights to things that the applicant did not actually invent.
discussion panel
Today Ashley is joined by an ever-popular group of IP professionals, including:
- David Cohen, Principal, Cohen Sciences
- Kristen Hansen, Patent Strategist at Aurora
- David Jackrel, President of Jackrel Consulting, said:
- Ty Davis, Aurora Patent Strategy Associate
Deepen your enablement
Enablement is a topic covered extensively in this podcast. This is a huge problem with many corners and complexities. To dig deeper into the other half of the bargain, check out below.
